Expected results

  • Application of a novel detection method based on a direct label-free acoustic wave transduction technique.
  • Development of microfluidic disposable inexpensive systems for handling minute amounts of ctDNA
  • Development of cost optimized methods to functionalize acoustic wave microresonators surface for DNA applications.
  • Development of a novel acoustic amplification technique, based on the combination of nanoparticles with DestiNa Genomics Smart nucleobases, capable of acting as a proofreading step in Liqbiopsens assay protocol.
  • Improving knowledge about CRC and associated treatments through a validation campaign with real samples.
  • Liqbiopsens approach paves the way for developing a completely new concept of direct genetic analysis avoiding costly and prone to errors amplifications steps.

LiqBiopSens operating concept

First, purified DNA will be obtained from 2-5 ml of plasma aliquots using commercially available DNA extraction kits. Then, DNA samples will be subjected to an isothermal pre-amplification step to enhance the number of molecules carrying mutations. This pre-amplification step will be carried out into a dedicated thermostatic chamber of Liqbiopsens platform.

Later, amplicon is injected inside the cartridge and processed according to a integrated work-flow. Amplicon DNA is denatured in a pre-treatment stage (1) by melting the dobule-stranded DNA to generate two single strands. In stage (2) single-stranded DNA molecules are transfered to sensor arrays containing DGL probes via a fluidic bypass. Following each amplicon hybridization with their corresponding DGL probe (stage 3), the mutations discriminated is carried out as for stage 4 by using (sensor arrays are immobilized on 4 channels.) novel A, T,C and G biotinylated-SMART Bases (each channel is interogated by individual B-SMART Base). 5) Subsequently, mutations are read out by acoustic reading – biotinylated- SMART Base are detected by specific recognition of streptavidin functionalized nanoparticles. In cases of multi mutations, individual amplified acoustic response will be measured individually on different sensor arrays.

RSS de esta página
Advance Wave Sensors SL
Destina Genomics Ltd.
Foundation for Research & Technology - Hellas
Servicio Andaluz de Salud - Hospital Universitario San Cecilio Granada
Sistemas Genómicos SL
Université Catholique de Louvain - ICTEAM
Co-funded by the Horizon 2020 Framework Programme of the European Union